GSK/Sirtris compounds dogged by assay artifacts

  title={GSK/Sirtris compounds dogged by assay artifacts},
  author={Charlie Schmidt},
  journal={Nature Biotechnology},
In January, scientists at Pfizer Global Research and Development, in Groton, Connecticut, reported that small molecules developed by Cambridge, Massachusetts–based Sirtris Pharmaceuticals do not activate the sirtuin pathway that has been linked to longevity. The disconcerting discovery, published in The Journal of Biological Chemistry (published online, doi:10.1074/jbc.M109.088682, 8 January 2010), is not the first to cast doubt on compounds that target sirtuins. In a paper published last… CONTINUE READING

From This Paper

Topics from this paper.

Similar Papers

Loading similar papers…